Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Zhejiang Provincial Science and Technology Cooperation Center Conference (July 2020)
17 slides from Optiscan Imaging's conference presentation, Jul 3, 2020
Slide 1: Optiscan Presentation
ASX Announcement 3 July 2020 Optiscan Presentation Optiscan Imaging Limited (ASX: OIL, Optiscan) provides a copy of the attached presentation from the Zhejiang Provincial Science and Technology Cooperation Center Conference. For and on behalf of Optiscan Imaging Limited: Darren Lurie Executive Chair
Slide 2: Optiscan Imaging Ltd (ASX:OIL)
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 3: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 30 June 2020. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may r
Slide 4: Notice
Notice Not an offer or financial productadvice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure docu
Slide 5: Corporate Snapshot
Corporate Snapshot Board Total Securities on Issue Darren Lurie – Executive Chairman ▪ 477,778,800 Ordinary Shares B.LLB (Hons) and B.COM(Hons) ▪ 25,600,000 unlisted options Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia)
Slide 6: OPTISCAN Introduction - Technology
OPTISCAN Introduction - Technology 4.7 mm Optiscan Technology diameter • Successful Development of hand-held Confocal Microscope for Medical and Research Imaging • World-leading and Patent Protected Technology • Real-time “Virtual Biopsy”, visualisation of human living tissue • Capture all Cancer Ce
Slide 7: Clinical Confocal Laser Endomicroscopy Applications
Clinical Confocal Laser Endomicroscopy Applications Clinical Applications and Devices: • Oral Cancer - InVivage® • Breast Cancer - InVivage® • Neurosurgery – CONVIVO® (Carl Zeiss Meditec Co-operation) Pre-clinical Device: FIVE2 (ViewVivo®) Cancer research, Tissue regeneration, Cell tracking, Photody
Slide 8: Oral Cancer Diagnosis, Survival Rates and Economic Cost
Oral Cancer Diagnosis, Survival Rates and Economic Cost 80 – 90 % Five Year Treatment cost for Early diagnosis Survival Rate1 Patients diagnosed with Stage 4 Oral Cancer are 2.5x more than patients 57% Five Year for diagnosed with Late diagnosis Stage 12 Survival Rate1 “need to investigate novel tec
Slide 9: New InVivage User Interface Designed for Doctors
New InVivage® User Interface Designed for Doctors Squamous epithelial cells and taste bud papillae in tongue (0.5mm x 0.5mm view)
Slide 10: OPTISCAN – Oral Cancer FY2020 Progress
OPTISCAN – Oral Cancer FY2020 Progress 3 Oral Cancer Studies and Trials: • Memorial Sloan Kettering Cancer Centre in New York (“MSK”) (on-going) • Melbourne Dental School in collaboration with Peter MacCallum Cancer Centre, Royal Melbourne Hospital, MSK and Australian Centre for Oral Oncology Resear
Slide 11: Chinese Dental Market Growth
Chinese Dental Market Growth Total Number of Dental Care Delivery Organisations KPPMG. (2016). Commercial opportunities in the dental care market in china. https://assets.kpmg/content/dam/kpmg/cn/pdf/en/2016/10/commercial-opportunities-in-the-dental-care-market-in-china.pdf
Slide 12: Dental Market Size - China
Dental Market Size - China • China: 48 Public Tertiary Dental Hospitals • Guangdong Province: 158 Stomatology Departments in General Hospitals, 14 Public and Private Dental Hospitals KPMG. (2016). Commercial opportunities in the dental care market in china. https://assets.kpmg/content/dam/kpmg/cn/pd
Slide 13: Breast Cancer - Most Common Cancer in Women
Breast Cancer - Most Common Cancer in Women 2.1 8.5% 2.5 Million Million 2.1 million new cases of 8.5% of all new cancer In 2021, the total number breast cancer predicted in cases in China are breast of existing breast cancer 2018 (globally) 1 cancer 2 patients in China will be 2.5 million3 ▪ Since
Slide 14: Optiscan - Breast Cancer Surgery
Optiscan - Breast Cancer Surgery Intraoperative Assessment of Breast Cancer Surgical Margin Normal Breast Tissue • Goal: Assist breast surgeons and pathologists to provide real-time cellular assessment of surgical margin. • Benefits: Reduce risk of residual tumour, need for repeat surgery, patient e
Slide 15: ZEISS CONVIVO – Carl Zeiss Meditec Co-operation
ZEISS CONVIVO® – CARL ZEISS MEDITEC (CZM) CO-OPERATION ZEISS CONVIVO® 297,000 • Target Application: Tumour margin detection in Brain Brain and CNS Cancer surgery cancer cases • FDA 510(k) Clearance and CE Mark obtained for p.a. CONVIVO® worldwide • Zeiss is an international leader in optics and opto
Slide 16: Distributor Strategy for China Pre-Clinical Market
Distributor Strategy for China Pre-Clinical Market • New multi-distributor model in China with appointment of exclusive distributor in Southern and Western China. ▪ South and West China: Guangzhou Yunxing (Purple andBlue) ▪ East China: Biotimes Technology Limited (Green) ▪ North China: To be Advised
Slide 17: Clinical and Research Imaging Platform Technology
Clinical and Research Imaging Platform Technology Brain ENT Airways Esophagus Pleura Stomach Breast Small bowel Pancreas Liver Cartilage Colon Tendons Ovary Bladder Cervix Prostate